肺轻链沉积性疾病继发于Sjögren病:一个病例报告
Xiaotong Xu1, Lingjian Wang1, Chunsheng Zhou2
1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
肺轻链沉积性疾病 (PLCDD) 是罕见的. 博尔特佐米布和德克萨米松 (BD) 的联合治疗显示,在一个患有PLCDD二次至初级Sjögren病 (pSjD) 的患者中显著改善.
科学领域:
- 肺部病理学 肺部病理学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 类风湿病学 类风湿病学
背景情况:
- 肺轻链沉积病 (PLCDD) 是一种罕见的疾病.
- PLCDD通常与淋巴细胞细胞增殖和自身免疫性疾病有关,例如原发性Sjögren病 (pSjD).
- 由于PLCDD的稀有性,目前的PLCDD管理策略尚未成熟.
研究的目的:
- 报告PSJD患者PLCDD的临床表现和成功管理.
- 评估博特佐米布和德克萨米松 (BD) 联合治疗在治疗PLCDD中的疗效.
主要方法:
- 一个42岁的女性病例报告,有psjD病史和复发性血.
- 临床,放射学和病理学评估证实了PLCDD.
- 在初始治疗失败后,治疗涉及用博特佐米布和德克萨米松 (BD) 联合治疗.
主要成果:
- 患者出现了复发性血栓塞,确认为PLCDD.
- 针对pSjD的初始疗法是无效的.
- 与BD结合治疗导致显著的临床和放射性改善.
结论:
- 波尔特佐米布和德克萨米松 (BD) 联合治疗是PLCDD的有希望的治疗方法,特别是当PSjD等自身免疫性疾病的继发性时.
- 这一案例突显了PLCDD向治疗的潜在突破.
更多相关视频
07:25Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
Published on: October 13, 2023
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
相关概念视频
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myasthenia Gravis ll: Pathophysiology
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
